A new study shows that neutralising GDF-15 restores immune response in advanced cancers resistant to PD-1 blockade.
Chugai obtains Japanese regulatory approval for Tecentriq for additional indication of alveolar soft part sarcoma, an ultra-rare disease: Tokyo Friday, February 21, 2025, 10:00 Hr ...
Ficerafusp alfa enters phase 2/3 trial for recurrent/metastatic head and neck cancer, evaluating its combination with Keytruda for first-line treatment.
The FDA granted breakthrough therapy status to first-line petosemtamab plus pembrolizumab for PD-L1–positive recurrent or ...
The registrational trial will include 212 patients who are newly diagnosed with advanced head and neck cancer.
Japanese drugmaker Chugai Pharmaceutical today announced gaining regulatory approval from the Ministry of Health, Labor and ...
SAN DIEGO, CA, USA I February 19, 2025 I Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and ...
Utrecht, The Netherlands Thursday, February 20, 2025, 15:00 Hrs [IST] ...
Researchers from Tianjin University have published data regarding development and preclinical characterization of a new anti-PD-L1/CD40 bispecific antibody (BsAb), BA-4415, designed to activate CD40 ...
Another antibody drug conjugate disitamab vedotin (an anti-HER2 antibody drug conjugate with MMAE payload) has also been shown to potentially pair well with immunotherapy. Disitamab vedotin + ...
The FDA granted fast track status to IBI363 for the treatment of patients with advanced squamous lung cancer after prior ...
Zacks.com on MSN3d
Exelixis Gains 6.7% Post Q4 Earnings: Is This the Right Time to Buy?Exelixis, Inc. EXEL reported better-than-expected fourth-quarter results. EXEL recorded earnings of 55 cents per share, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback